Drug Trial Radar · NCT07082114
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Jul 14, 2025
Primary completion
Feb 16, 2027
Study completion May 17, 2027
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin.
Conditions
- Type 2 Diabetes
Interventions
HDM1002 100 mgDrug
HDM1002 tablets, 100 mg once daily, 52 weeks
HDM1002 200 mgDrug
HDM1002 tablets, 200 mg once daily, 52 weeks
HDM1002 400 mgDrug
HDM1002 tablets, 400 mg once daily, 52 weeks
Dapagliflozin (DAPA)Drug
dapagliflozin 10mg will be provided
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 40Time frame: Baseline, Week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yueyang People's Hospital
Yueyang, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.